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BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive B-cell lymphoma with poor prognosis, requiring novel anticancer
strategies.
METHODS: Mantle cell lymphoma cell lines with known p53 status were treated with GUT-70, a tricyclic coumarin derived from
Calophyllum brasiliense, and the biological and biochemical consequences of GUT-70 were studied.
RESULTS: GUT-70 markedly reduced cell proliferation/viability through G1 cell cycle arrest and increased apoptosis, with greater
sensitivity in mutant (mt)-p53-expressing MCL cells than in wild-type (wt)-p53-bearing cells. Mechanistically, GUT-70 showed binding
affinity to heat-shock protein 90 (Hsp90) and ubiquitin-dependent proteasomal degradation of Hsp90 client proteins, including cyclin
D1, Raf-1, Akt, and mt-p53. Depletion of constitutively overexpressed cyclin D1 by GUT-70 was accompanied by p27 accumulation
and decreased Rb phosphorylation. GUT-70 induced mitochondrial apoptosis with Noxa upregulation and Mcl-1 downregulation in
mt-p53 cells, but Mcl-1 accumulation in wt-p53 cells. Noxa and Mcl-1 were coimmunoprecipitated, and activated BAK. Treatment
with a combination of GUT-70 and bortezomib or doxorubicin had synergistic antiproliferative effects in MCL cells that were
independent of p53 status.
CONCLUSION: GUT-70 has pronounced antiproliferative effects in MCL with mt-p53, a known negative prognostic factor for MCL,
through Hsp90 inhibition. These findings suggest that GUT-70 has potential utility for the treatment of MCL.
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Mantle cell lymphoma (MCL) is characterised by an aggressive
clinical course, with rapid relapse after an initial response or
primary resistance to standard chemotherapy (Jares et al, 2007).
The t(11,14)(q13;32) translocation of MCL leads to overexpression
of cyclin D1, which is believed to be associated with oncogenesis
by causing instability of the G1/S checkpoint through promotion of
cyclin-dependent kinase activity and through sequestration of the
Cip/Kip family of cyclin-dependent kinase inhibitors (Sherr and
Roberts, 1999; Quintanilla-Martinez et al, 2003). These activities
facilitate phosphorylation and inactivation of the retinoblastoma
(Rb) G1/S checkpoint protein, resulting in cell cycle progression. It
has been demonstrated, however, that overexpression of cyclin D1
itself is not sufficient for development of MCL, suggesting that
additional genetic events might be necessary for oncogenesis
(Bodrug et al, 1994), particularly as apoptosis-related genes such
as p53, INK4a/ARF, and ATM are dysregulated in MCL (Ferna `ndez
et al, 2005; Greiner et al, 2006).
In MCL, mutation/overexpression of p53 is reported as an
adverse prognostic indicator (Jares et al, 2007). As many of the
antitumour effects mediated by chemotherapeutic agents depend
on a p53-related pathway, resistance to chemotherapy often
develops through impaired p53 signalling (Do ¨hner et al, 1995).
The 26S proteasome inhibitor bortezomib retains activity in p53-
mutant (mt-p53) cells and has demonstrated single-agent efficacy
in relapsed or refractory MCL, which is, however, based mainly on
prolonged response rather than on an increase in ultimate survival
rate (Goy et al, 2009).
Therefore, development of novel compounds that target p53-
independent signalling pathways is of considerable interest in the
treatment of this disease.
We have reported that the newly discovered anticancer agent
GUT-70, a natural product derived from the stem bark of
Calophyllum brasiliense, demonstrated cytotoxic efficacy in
human leukaemic cells (Kimura et al, 2005). GUT-70 (Figure 1),
characterised as a tricyclic coumarin with the formula
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s5-methoxy-2,2-dimethyl-6-(2-methyl-1-oxo-2-butenyl) -10-propyl-
2H,8H-benzo[1,2-b;3,4-b0]dipyran-8-one (C23H26O5), significantly
inhibited leukaemic cell growth with a median inhibitory con-
centration (IC50) of 2-5mM without repressing colony formation
by normal haematopoietic progenitors or proliferation of
normal human hepatocytes at concentrations up to 30mM (Kimura
et al, 2005).
Coumarin antibiotics have been reported to bind the newly
discovered C-terminal ATP binding site of 90kDa heat-shock
protein (Hsp90), a molecular chaperone responsible for the folding
and conformational maintenance of client proteins (Marcu et al,
2000; Issacs et al, 2003; Pratt and Toft, 2003; Donnelly et al, 2008).
Hsp90 inhibition results in degradation of misfolded Hsp90 clients
through ubiquitination, followed by proteasome-mediated hydro-
lysis (Zhang et al, 2004). As many of the Hsp90 client proteins
contribute to cancer cell proliferation, Hsp90 has emerged as a
promising target for cancer chemotherapy (Issacs et al, 2003;
Donnelly et al, 2008).
In this study, GUT-70 demonstrated antiproliferative and
proapoptotic activities with more prominent efficacy in mt-p53-
bearing MCL cells than in those with wild-type (wt) p53. GUT-70
showed binding affinity to Hsp90, and reduced expression of
Hsp90 client proteins such as mt-p53, Raf-1, cyclin D1, and Akt.
The intrinsic apoptotic pathway was activated by GUT-70 through
upregulation of Noxa and BAK activation. The combination of
GUT-70 with bortezomib or doxorubicin yielded synergistic
antiproliferative effects independent of p53 status. These findings
indicate possible efficacy and a rationale for further exploration of
GUT-70 as a new therapeutic strategy for MCL.
MATERIALS AND METHODS
Cell lines and culture conditions
Four MCL cell lines were used in this study: JVM-2 (Melo et al,
1986), Granta 519 (Jadayel et al, 1997) and MINO (Lai et al, 2002)
were kindly provided by Dr M Raffeld, and Jeko-1 (Raynaud et al,
1993) was a gift from Dr M Seto. Granta 519 and JVM-2 express
wt-p53, whereas Jeko-1 and MINO express p53 mutations (Jeko-1,
loss of p53 expression; MINO, mutation at codon 147 (valine-
glycine)) (Raynaud et al, 1993; Lai et al, 2002). JVM-2, Jeko-1 and
MINO were cultured in RPMI 1640 medium containing 15% fetal
bovine serum (FBS) and 1% penicillin/streptomycin. Granta 519
was grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 15% FBS. Cells were first acclimated in RPMI
1640 or DMEM containing 5% FBS for 16h before exposure to
GUT-70 (Nippon Shinyaku, Kyoto, Japan) (Kimura et al, 2005).
Control cells were treated with an equivalent amount of dimethyl
sulphoxide (DMSO). Doxorubicin was obtained from Sigma
(St Louis, MO, USA) and bortezomib was provided by Millennium
(Cambridge, MA, USA). Human osteosarcoma cell line U2OS
transfected with the histone cluster 1 (H2BK) and enhanced green
fluorescent protein (EGFP) genes, U2OS-H2BK-EGFP, was grown
in DMEM supplemented with 10% FBS and used for morphological
observation. U2OS expresses wt-p53 (Flørenes et al, 1994).
Cell viability/proliferation assay
Cell viability was assessed by the Trypan blue dye exclusion
method, and cell proliferation was determined by the CellTiter 96
AQueous One Solution Cell Proliferation Assay (MTS; Promega,
Madison, WI, USA).
Apoptosis analysis
Apoptotic cell death was evaluated through annexin V (Roche
Diagnostic, Indianapolis, IN, USA) and propidium iodide (PI)
positivities by a FACScan flow cytometer and Cell Quest software
(Becton Dickinson Immunocytometry Systems, San Jose, CA,
USA). The extent of drug-specific apoptosis was assessed by
the following formula: % specific apoptosis¼(test control) 100/
(100 control).
Flow cytometric analysis of cell cycle and BAK activation
Cell cycle distribution was determined by flow cytometric analysis
of PI-stained nuclei. DNA content was determined by FACScan
flow cytometer and CellQuest software. BAK activation was
analyzed as previously described (Samraj et al, 2006). Briefly, cells
were fixed and permeabilized using the DAKO IntraStain kit
(DakoCytomation, Glostrup, Denmark) according to the manufac-
turer’s instructions. Cells were then stained with conformation-
specific monoclonal antibody against BAK (y164; Abcam,
Cambridge, MA, USA) or isotype-matched control antibody for
30min at room temperature, followed by incubation with
Alexafluor 488-labeled chicken anti-rabbit secondary antibody
(Molecular Probes, Eugene, OR, USA) for 30min on ice in the
dark. After the washing step, conformational change of BAK was
analyzed by a FACScan flow cytometer.
Western blot analysis and immunoprecipitation
Cells were solubilised in lysis buffer (phosphate-buffered saline
solution (PBS), 1  cell lysis buffer (Cell Signaling Technology,
Danvers, MA, USA), 1  protease inhibitor (Roche), and 1 
phosphatase inhibitor cocktails I and II (Calbiochem, San Diego,
CA, USA)), and incubated for 30min on ice. Total protein (20mg)
was separated by sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS–PAGE), immunoblotted with appropriate
antibodies, and reacted with enhanced chemiluminescence
reagent (Amersham Biosciences, Piscataway, NJ, USA); signals were
detected by a luminescent image analyser (LAS-1000 plus; Fujifilm,
Tokyo, Japan). The anti-a-tubulin or anti-b-actin blot was used
in parallel as a loading control. For immunoblotting, the follo-
wing antibodies were used: p21
Cip1/WAF1,p 2 7
KIP1, and Mcl-1
(BD-Pharmingen, San Diego, CA, USA); p53 (DO-7; Dako,
Carpinteria, CA, USA); Noxa (Calbiochem); a-tubulin (Sigma-
Aldrich, St Louis, MO, USA); Puma (Upstate Biotechnology, Lake
Placid, NY, USA); LC-3 (MBL, Nagoya, Japan); ubiquitin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA); and Hsp70, c-Raf, Akt,
ERK1/2, phosphorylated-ERK1/2
Thr202/Tyr204(p-ERK1/2), cyclin D1,
phosphorylated Rb
Ser780 (p-Rb), Bim, BAK, cleaved caspase-9,
cleaved caspase-3, b-actin, and horseradish peroxidase-linked anti-
mouse and anti-rabbit IgG (all from Cell Signaling Technology).
Protein lysates were subjected to immunoprecipitation using anti-
Mcl-1 (Santa Cruz Biotechnology).
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Figure 1 Chemical structure of GUT-70.
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The Hsp90a inhibitor screening assay kit with Hsp90a recombi-
nant enzyme and fluorescein isothiocyanate (FITC)-labelled
geldanamycin was used (BPS Bioscience, San Diego, CA, USA).
The competition of fluorescence-labelled geldanamycin for bind-
ing to purified recombinant Hsp90a was measured by Flex Station
3 (Molecular Devices, Sunnyvale, CA, USA).
Morphological observation
U2OS-H2BK-EGFP cells (2.0 10
5 per ml) were cultured in a
35-mm dish and treated with 5mM GUT-70 or DMSO only. Each
dish was placed on the stage of a light microscope equipped with a
digital camera (BZ-8000; Keyence, Osaka, Japan) at 371C under a
humidified atmosphere of 5% CO2. Video images were collected
over the period from 12 to 48h after treatment.
mRNA quantification by real-time reverse-transcriptase
PCR (RT–PCR)
Total RNAs were extracted from cells with the RNeasy Mini Kit
(Qiagen, Hilden, Germany). First-strand cDNA synthesis was
performed with oligo(dT) as primer (Superscript II System;
Invitrogen, Carlsbad, CA, USA). Real-time reverse-transcriptase
PCR was performed by the Model 7500 Real-time PCR System
(Applied Biosystems, Foster City, CA, USA). Expression of Noxa
and GAPDH mRNA was detected by TaqMan Gene Expression
Assays (Noxa: Hs00560402_m1, GAPDH: Hs99999905_m1; Applied
Biosystems). The PCR cycle number that generated the first
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Figure 2 GUT-70-induced cell growth inhibition, apoptosis, and cell cycle arrest in MCL. (A) JVM-2, Granta 519, Jeko-1, and MINO cells were treated
with the indicated concentrations of GUT-70 for 48h, and the percentages of apoptotic cells were quantified by annexin V/PI staining. (B) Representative
flow cytometric histograms of PI-treated cells after 24h of GUT-70 treatment at indicated concentrations. The percentages of G0/G1-, S- and G2/M-phase
cells were assessed in total viable cells (bar graphs).
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Ct) was determined. The abundance of each transcript of Noxa
relative to that of GAPDH was calculated as follows: relative
expression¼100 2 exp [ DCt], where DCt is the mean Ct of
the transcript of interest minus the mean Ct of the transcript for
GAPDH. The Ct data from duplicate PCRs were averaged for
calculation of relative expression.
Statistical analysis
Cytotoxicity was assessed by the Chou-Talalay method (Chou and
Talalay, 1984) using Calcusyn software (Biosoft, Cambridge, UK).
The combination index (CI) values indicate degree of synergism:
strong synergism (0.3–0.7), moderate synergism (0.7–0.85), and
slight synergism (0.85–0.9).
RESULTS
GUT-70 induces apoptosis and cell cycle arrest in MCL cells
Treatment with GUT-70 (Figure 1) for 48h resulted in dose-
dependent cell growth inhibition detected by MTS cell prolifera-
tion assay (IC50: Granta 519, 6. 3mM; JVM-2, 4.5mM; Jeko-1, 1.7mM;
MINO, 1.5mM).
To determine whether the inhibition of cell growth by GUT-70
was associated with apoptosis and/or cell cycle arrest, we
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Figure 2 Continued.
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sconducted flow cytometric analysis of annexin V/PI-stained and
PI-stained nuclei. As shown in Figure 2A, 48h of GUT-70
treatment induced dose-dependent increases of annexin V
positivity in all cell lines; this effect was more pronounced in
mt-p53-bearing Jeko-1 and MINO cells than in wt-p53-bearing
Granta 519 and JVM-2 cells (specific apoptosis by 5mM GUT-70:
40.3% for Granta 519, 40.1% for JVM-2, 78.8% for Jeko-1, 79.9%
for MINO). The PI cell cycle histograms further demonstrated that
GUT-70 increased the sub-G1 fraction in a time-dependent manner
at a lower dose for mt-p53 cells than for wt-p53 cells; sub-G1
fractions at 24 and 48h were 4.6 and 10.7% for Granta 519 (5mM
GUT-70), 14.8 and 34.7% for JVM-2 (5mM), 5.2 and 19.3% for Jeko-
1( 1mM), and 12.0 and 34.9% for MINO (1mM). Whereas GUT-70
impeded G1-S cell cycle progression in JVM-2 and Granta 519 cells,
G1-S arrest was minimal in MINO and Jeko-1 cells (Figure 2B).
These data suggest that GUT-70-induced cell growth inhibition
resulted in part from cell cycle arrest at the G0/G1 checkpoint and
in part from apoptosis induction.
GUT-70 downregulates mutated p53 and cyclin D1 and
accumulates p27
We next investigated changes in cell cycle regulatory proteins
associated with GUT-70 treatment. As shown in Figure 3A, GUT-70
induced p53/p21 accumulation in JVM-2 cells, but did not increase
p53/p21 expression in Granta 519 cells. In Jeko-1 cells, basal
p53/p21 expression was not detectable and was unaffected by
GUT-70. Notably, expression of the overexpressed mt-p53 protein
was reduced in MINO cells by 24h exposure to GUT-70, with-
out detectable p21 expression. The expression level of p27 was
upregulated by GUT-70, irrespective of p53 status. GUT-70
diminished the highly expressed cyclin D1 in all tested MCL cells
except JVM-2, and resulted in substantial decreases in Rb
phosphorylation in all tested cells (Figure 3).
GUT-70 induces degradation of Hsp90 substrate proteins
The coumarin antibiotics have been reported to bind to Hsp90
(Marcu et al, 2000). To investigate whether GUT-70 has binding
affinity for Hsp90, a competitive binding assay was performed
using geldanamycin, a well-characterised ATP competitive
inhibitor (Gooljarsingh et al, 2006). GUT-70 demonstrated dose-
dependent inhibition of geldanamycin binding to Hsp90, which
indicated the binding activity of GUT-70 to Hsp90 (Figure 3B). The
degradation by GUT-70 of Hsp90 client proteins, such as Raf-1
and its downstream ERK1/2 and phospho ERK1/2, as well as Akt
(Pratt and Toft, 2003; Zhang et al, 2004, 2005), was detected by
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Figure 3 (A) GUT-70 effects on Hsp90 client proteins. MCL cells were treated with GUT-70 (JVM-2, 5mM; Granta 519, 5mM; Jeko-1, 1mM; MINO, 5mM)
for indicated times. Cells were subjected to lysis and analysed by western blot. Western blot images are representative results from three independent
experiments. (B) GUT-70 competitively inhibited geldanamycin binding to the Hsp90a subunit. The competition of GUT-70 with FITC-labelled
geldanamycin for binding to purified recombinant Hsp90a was measured. Fluorescence was measured at lex 485nm and at lem 525nm. Results shown are
means±s.d. from three independent experiments. (C) GUT-70 induced protein ubiquitination. JVM-2 and MINO cells were treated with 5mM GUT-70 for
24h, subjected to lysis, and immunoblotted for ubiquitin. Representative results are shown from three independent experiments. (D) Proteasome inhibitor
bortezomib prevented GUT-70-mediated decreased expression of c-Raf. JVM-2 and MINO cells were treated with 5mM GUT-70 and/or 10nM bortezomib
for 24h, subjected to lysis, and immunoblotted for c-Raf. Western blot images are representative results from three independent experiments.
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swestern blot analysis in all tested MCL cells (Figure 3A). Cyclin D1
and mt-p53, the expression of which was repressed by GUT-70, are
known substrate proteins of Hsp90 (Zhang et al, 2004; Muller et al,
2008). Furthermore, GUT-70 increased expression of Hsp70, a
marker of Hsp90 inhibition (Elo et al, 2005; Bao et al, 2009), in
Granta 519, JVM-2, and MINO cells. In Jeko-1 cells, however,
Hsp70 was detected at a level insufficient to be reliable as a marker
without further induction by GUT-70 (Figure 3A).
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Figure 4 Modulation of apoptosis-related protein levels by GUT-70. MCL cells were treated with GUT-70 (JVM-2, 5mM; Granta 519, 5mM; Jeko-1, 1mM;
MINO, 5mM) for the indicated times. (A) Cells were subjected to lysis, then apoptosis-related proteins and macroautophagy marker LC3 were analysed by
western blot. Western blot images are representative results from three independent experiments. (B) Cells were harvested after 18h treatment with
GUT-70, and Noxa mRNA expression levels were detected by TaqMan RT–PCR analysis. The abundance of transcripts of Noxa relative to GAPDH
transcripts was determined as described in Materials and Methods. Graphs show the representative data from two independent experiments with similar
results. (C) Cells were treated with GUT-70 for 24h, and Mcl-1 immunoprecipitation was performed as described in Materials and Methods. Total extracts
were analysed by western blotting for Noxa. Western blot images are representative results from three independent experiments. (D) Cells were treated
with GUT-70 for 24h, then conformational changes in BAK were measured by intracellular flow cytometry as described in Materials and methods. To block
the caspase activation-mediated conformational changes of BAK, cells were preincubated for 1h with 100mM Z-VAD-FMK. Data represent duplicate
experiments. *Po0.01; **Po0.05. RE, relative expression.
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misfolded and ubiquitinated by Hsp90 inhibition, and are then
downregulated by proteasomal degradation (Issacs et al, 2003;
Zhang et al, 2004), we next tried to determine whether GUT-70
induces protein ubiquitination followed by proteasomal degrada-
tion in wt-p53-expressing JVM-2 and mt-p53-expressing MINO
cells. As expected, GUT-70 treatment elevated the level of protein
ubiquitination (Figure 3C); subsequent treatment with proteasome
inhibitor bortezomib prevented degradation of c-Raf by GUT-70
(Figure 3D). Taken together, these data indicate the interaction of
GUT-70 with Hsp90 and the destabilisation of Hsp90 client
proteins by GUT-70.
Effect of GUT-70 on apoptosis-related proteins
To characterise the mechanism of GUT-70-induced cell death in
MCL cells, we analysed the expression of apoptosis-related Bcl-2
family proteins, the BH3-only proteins Noxa, Puma, and Bim, and
the other Bcl-2 family proteins, Mcl-1 and BAK, in MCL cell lines.
Results show that GUT-70 induced substantial accumulation of
Noxa but not of Puma (Figure 4A). Mutant-p53-bearing MCL cells
demonstrated earlier Noxa induction than wt-p53 cells; peak
induction of Noxa was observed after 1h of GUT-70 treatment in
MINO, after 8h in Jeko-1, and after 24h in JVM-2 and Granta 519
cells. GUT-70 induced upregulation of Noxa mRNA levels in all
tested cells (Figure 4B).
After 24h of GUT-70 treatment, levels of antiapoptotic protein
Mcl-1 were increased in JVM-2 and Granta 519 cells, but decreased
in Jeko-1 and MINO cells (Figure 4A). It is known that Noxa
binds preferentially to Mcl-1 (Warr and Shore, 2008), triggers BAK
or Bim release from Mcl-1, and then starts the mitochondrial
apoptotic pathway (Willis et al, 2005; Hauck et al, 2009). Concor-
dantly, we detected coimmunoprecipitation between Noxa and
Mcl-1 (Figure 4C) in JVM-2 and Granta 519 cells, both of which
showed accumulation of Mcl-1 induced by GUT-70. Although total
BAK expression levels remained, consistently independent of
GUT-70 treatment (Figure 4A), flow cytometric analysis revealed
a pronounced increase of activated BAK in MINO, moderate
activation in Jeko-1, and only slight activation in JVM-2 and
Granta 519 cells after GUT-70 treatment (Figure 4D), activities that
are in inverse relation to Mcl-1 expression levels.
Proapoptotic BH-3-only protein Bim was induced by GUT-70 at
24h in JVM-2 cells but not in the other cell lines (Figure 4A).
GUT-70 does not induce macroautophagy
Increasing evidence indicates that autophagy is one of the
important mechanisms of anticancer reagent-induced cell death
(Tsujimoto and Shimizu, 2005). In mammals, three modes of
autophagy have been identified: macroautophagy, microauto-
phagy, and chaperone-mediated autophagy (Levine and Klionsky,
2004). To investigate the possibility that GUT-70 promotes
macroautophagy, we examined the conversion of light chain 3
(LC3) from LC3-I to LC3-II, a marker of autophagosome formation
(Kabeya et al, 2000). Whereas LC3-II was moderately induced by a
low serum culture condition (5%, 40h) in wt-p53-expressing
JVM-2 and Granta 519 cells, there was no change in accumulation
of LC3-II following further treatment with GUT-70 (24h). In mt-
p53-bearing MINO and Jeko-1 cells, neither serum starvation nor
GUT-70 treatment induced LC3-II accumulation (Figure 4A).
To assess the morphological changes induced by GUT-70,
U2OS-H2BK-EGFP cells were sequentially photographed after
exposure to GUT-70. Cells underwent morphological alterations,
including cytoplasmic swelling and vacuolisation after 24h of
GUT-70 exposure (cellular oncosis), and cell death peaked at 36h
(secondary necrosis) (Supplementary Material 1 for Quick-Time
movies) (Majno and Joris, 1995; Lemasters et al, 1998; Van
Cruchten and Van Den Broeck, 2002).
Combination of GUT-70 with bortezomib or doxorubicin
has synergistic effects on MCL growth inhibition
To determine whether GUT-70 potentiates the commonly used
chemotherapeutic agents, we assessed the effects of combinations
of GUT-70 with bortezomib, a selective inhibitor of the 26S
proteasome, or doxorubicin, a conventional chemodrug for MCL,
on viability of wt-p53 JVM-2 and mt-p53 MINO cells. As shown in
Figure 5A, both of these combination treatments had observable
synergistic effects in both cell types 48h after exposure. The
averaged CI values of GUT-70/bortezomib treatment were 0.59 for
JVM2 and 0.73 for MINO; for GUT-70/doxorubicin, 0.37 for JVM2
and 0.35 for MINO, indicating strong and moderate synergism,
respectively.
DISCUSSION
The natural product-derived tricyclic coumarin GUT-70 exhibited
single-agent antiproliferative and proapoptotic activities against
MCL cell lines as a novel Hsp90 inhibitor. GUT-70’s dose-
dependent inhibition of geldanamycin binding to Hsp90a indicates
that GUT-70 has direct binding activity to Hsp90, by which GUT-
70 induces conformational change in the Hsp90 molecule and
interferes with its binding of geldanamycin. This finding agrees
with that of previous studies showing that coumarin antibotic
novobiocin binds to the Hsp90 C-terminal ATP binding site and
affects the binding of geldanamycin at the Hsp90 N-terminal
domain through close interaction between amino and carboxy
termini in solution (Csermely et al, 1998; Hartson et al, 1999;
Marcu et al, 2000; Donnelly et al, 2008). GUT-70 induced depletion
of Hsp90 client proteins mt-p53, Raf-1, cyclin D1, and Akt, and
increased Hsp70, a marker of Hsp90 inhibition; these findings,
along with the ubiquitin-dependent proteasomal degradation of
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Figure 5 Synergistic interaction between GUT-70 and bortezomib or
doxorubicin in MCL cells. JVM2 and MINO cells were cultured in the
presence of escalating doses of GUT-70 and bortezomib (BTZ) (A)o r
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Results are expressed as means±s.d. percentage of viable cell numbers in
control cells.
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Hsp90 inhibitor.
It is important that mt-p53-expressing MCL cells were more
sensitive to GUT-70-induced apoptosis than wt-p53-bearing MCL
cells. In mt-p53 cells, prominent GUT-70-induced apoptosis was
accompanied by minimal cell cycle arrest, which is consistent with
a previous report of G2/M checkpoint abrogation in p53/p21-
impaired cells through downregulation of Chk1 and Wee1 by
Hsp90 inhibitor that resulted in premature mitotic entry and
mitotic death (Tse et al, 2009).
Furthermore, GUT-70 induced the most pronounced apoptosis
in MINO cells in which GUT-70 treatment depleted overexpressed
mt-p53. mt-p53 is known to confer the additional ‘gain of function’
as the transcription regulator. Transcriptional activation by
mt-p53 has been reported for MDR1 (Sampath et al, 2006),
c-MYC (Frazier et al, 1998), or GRO1 (Yan and Chen, 2009),
resulting in cell proliferation, antiapoptosis, and tumourigenicity
(Blandino et al, 1999). GUT-70-induced degradation of mt-p53 may
successfully repress these oncogenic transcriptional activations.
Another important finding of this study is the prominent
p53-independent Noxa upregulation by GUT-70. Whereas Noxa
had been proposed to be a critical mediator of p53-dependent
apoptosis (Oda et al, 2000), p53-independent upregulation of Noxa
has been described in MCL and B-cell chronic lymphocytic
leukaemia (Pe ´rez-Gala ´n et al, 2006; Smit et al, 2007). Furthermore,
GUT-70 induced Noxa protein accumulation extremely early (1h)
in mt-p53-bearing MINO cells, indicating independence from
transcriptional gene induction. Recently, Noxa degradation by
direct interaction with a spliced isoform of the Kruppel-like
tumour suppressor (KLF6-SV1) (Difeo et al, 2009), or by
posttranscriptional stabilisation/destabilisation of Bim mRNA
(Matsui et al, 2007), has been reported. Our findings indicate the
possibility of posttranscriptional Noxa stabilisation by GUT-70,
which requires further elucidation.
The preferred binding partner of Noxa is the multidomain
antiapoptotic Bcl-2 family member Mcl-1. In response to apoptotic
stimuli, Noxa binds to Mcl-1, which ultimately leads to activation of
BAK by releasing BAK from the BAK Mcl-1 complex, and triggers
BAK-mediated cell death (Chen et al, 2005; Warr and Shore, 2008)
(Figure S, Supplementary Material 2 (Kuroda and Kimura, 2007)).
The balance between Noxa and Mcl-1 is proposed to determine cell
fate as death versus survival (Mei et al, 2007). GUT-70-induced BAK
activation and sequential apoptosis were associated with Mcl-1
accumulation levels; high levels in less-sensitive wt-p53 cells and low
levels in highly sensitive mt-p53 cells were consistent with previous
reports (Pe ´rez-Gala ´n et al, 2006; Mei et al, 2007).
Autophagy is known to promote both autophagic cell death
and cell survival (Kamitsuji et al, 2008). Although GUT-70 did
not affect autophagosome formation, Hsp90 clients have been
shown to be degraded through chaperone-mediated autophagy
(Shen et al, 2009). The role of GUT-70 in induction of chaperone-
mediated autophagy requires further elucidation.
The observed morphological changes in GUT-70-treated cells
(e.g., swelling cytoplasm) indicate cellular oncosis (Van Cruchten
and Van Den Broeck, 2002), which shares certain mechanisms and
alterations with apoptosis, such as loss of mitochondrial perme-
ability and membrane potential (Lemasters et al, 1998).
Furthermore, our results demonstrate that GUT-70 can syner-
gise the cytotoxic effects of the proteasome inhibitor bortezomib
and the widely used genotoxic chemotherapeutic agent doxor-
ubicin in MCL cells (Brody and Advani, 2006; Goy et al, 2009),
regardless of p53 status. Previously, a combination of Hsp90
inhibitor geldanamycin and bortezomib was demonstrated to
simultaneously disrupt Hsp90 and proteasome function, promote
accumulation of ubiquitinated proteins, and enhance antitumour
activity in human breast cancer cells (Mimnaugh et al, 2004, 2006).
Whereas bortezomib induces longer-term remission (Goy et al,
2009), patients ultimately succumb to the poor clinical outcome,
and there is a critical need to develop the most effective
combination. The synergistic effects of GUT-70 and bortezomib
may offer more efficacy and flexibility to the treatment of MCL
with bortezomib. The antiproliferative effect of the combination of
doxorubicin and GUT-70 was consistent with the previous findings
for doxorubicin and Hsp-90 inhibitor 17-(dimethylaminoethyl-
amino)-17-demethoxygeldamanycin (DMAG), which induced
premature mitosis, followed by apoptosis, by bypassing the G2/M
checkpoint in lymphoma cells (Robles et al, 2006). The synergy
with doxorubicin suggests that addition of GUT-70 may allow
reduction in the therapeutic dose of doxorubicin, which could
potentially reduce its genotoxic side effects (Brody and Advani,
2006). A development of in vivo studies of these combination
treatments for MCL is further required.
In conclusion, our results demonstrate that the novel anticancer
agent GUT-70, a tricyclic coumarin, inhibits cell proliferation by
depleting Hsp90 substrates cyclin D1, Akt, and Raf-1, and induces
mitochondrial apoptotic cell death with upregulation of Noxa in
MCL cells. Notably, these effects are substantially pronounced
in MCL cells with mt-p53, a known negative prognostic factor for
MCL. These findings suggest that GUT-70 has potential utility for
the treatment of MCL.
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